Ketamine hydrochloride is a Small Molecule owned by Seelos Therapeutics, and is involved in 5 clinical trials, of which 1 was completed, 3 are ongoing, and 1 is planned.
Ketamine acts as AMPA receptor agonist and NMDA receptor antagonist. AMPA receptors are responsible for the bulk of fast excitatory synaptic transmission throughout the CNS. The drug candidate intensifies the action of the AMPA type glutamate receptors in the brain, which may in turn influence cognitive functions such as thinking, attention, and memory. It also modulates excitatory neurotransmission mediated by NMDA receptors by binding to the strychnine-insensitive glycine recognition site of the NMDA receptor complex.The drug candidate enhances excitatory communication, thereby partially or completely restoring the brains excitatory communication.
The revenue for Ketamine hydrochloride is expected to reach a total of $244m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ketamine hydrochloride NPV Report.
Ketamine hydrochloride is currently owned by Seelos Therapeutics.
Ketamine hydrochloride Overview
Ereska (intranasal ketamine, PMI-150, SLS-002) is under development for the treatment of suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The drug candidate is administered through intranasal route. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA) and glutamate ionotropic receptor NMDA type subunit.
It was also under development for the treatment of postoperative pain and pain in cancer patients.
Seelos Therapeutics Overview
Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.
The operating loss of the company was US$63.9 million in FY2021, compared to an operating loss of US$18.8 million in FY2020. The net loss of the company was US$66.1 million in FY2021, compared to a net loss of US$19.1 million in FY2020.
Quick View – Ketamine hydrochloride
|Highest Development Stage|